KR102053674B1 - 비-천연 컨센서스 알부민 결합 도메인 - Google Patents

비-천연 컨센서스 알부민 결합 도메인 Download PDF

Info

Publication number
KR102053674B1
KR102053674B1 KR1020147035989A KR20147035989A KR102053674B1 KR 102053674 B1 KR102053674 B1 KR 102053674B1 KR 1020147035989 A KR1020147035989 A KR 1020147035989A KR 20147035989 A KR20147035989 A KR 20147035989A KR 102053674 B1 KR102053674 B1 KR 102053674B1
Authority
KR
South Korea
Prior art keywords
ala
lys
glu
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035989A
Other languages
English (en)
Korean (ko)
Other versions
KR20150016585A (ko
Inventor
스티븐 제이콥스
Original Assignee
얀센 바이오테크 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 바이오테크 인코포레이티드 filed Critical 얀센 바이오테크 인코포레이티드
Publication of KR20150016585A publication Critical patent/KR20150016585A/ko
Application granted granted Critical
Publication of KR102053674B1 publication Critical patent/KR102053674B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020147035989A 2012-05-25 2013-05-23 비-천연 컨센서스 알부민 결합 도메인 Active KR102053674B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651642P 2012-05-25 2012-05-25
US61/651,642 2012-05-25
US201361776918P 2013-03-12 2013-03-12
US61/776,918 2013-03-12
PCT/US2013/042429 WO2013177398A2 (en) 2012-05-25 2013-05-23 Non-natural consensus albumin binding domains

Publications (2)

Publication Number Publication Date
KR20150016585A KR20150016585A (ko) 2015-02-12
KR102053674B1 true KR102053674B1 (ko) 2019-12-09

Family

ID=49622071

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035989A Active KR102053674B1 (ko) 2012-05-25 2013-05-23 비-천연 컨센서스 알부민 결합 도메인

Country Status (15)

Country Link
US (3) US9156887B2 (enExample)
EP (1) EP2855509B1 (enExample)
JP (3) JP2015519345A (enExample)
KR (1) KR102053674B1 (enExample)
CN (1) CN104470944B (enExample)
AU (2) AU2013266215B2 (enExample)
BR (1) BR112014029409B1 (enExample)
CA (1) CA2874646C (enExample)
DK (1) DK2855509T3 (enExample)
EA (1) EA036487B1 (enExample)
ES (1) ES2670442T3 (enExample)
IL (2) IL235808A (enExample)
MX (1) MX355041B (enExample)
PT (1) PT2855509T (enExample)
WO (1) WO2013177398A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EP2971290A4 (en) * 2013-03-14 2017-03-01 The Governing Council Of The University Of Toronto Scaffolded peptidic libraries and methods of making and screening the same
CA2979973A1 (en) * 2015-04-29 2016-11-03 Mediolanum Farmaceutici S.P.A. A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016204884A1 (en) * 2015-06-18 2016-12-22 Albert Einstein College Of Medicine, Inc. Fgf receptor ligands for treating diabetes and obesity
WO2017081082A2 (en) * 2015-11-09 2017-05-18 Curevac Ag Optimized nucleic acid molecules
CN106699842B (zh) * 2015-11-17 2020-06-12 上海交通大学 一种新的抗炎小分子多肽及其应用
CN109153711B (zh) 2016-03-01 2022-04-26 伊利诺伊大学理事会 具有降低的l-谷氨酰胺酶活性和增强的稳定性的l-天冬酰胺酶变体和融合蛋白
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
JP7104703B2 (ja) 2016-12-14 2022-07-21 ヤンセン バイオテツク,インコーポレーテツド Cd8a結合フィブロネクチンiii型ドメイン
JP7332157B2 (ja) * 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素2(ace2)の活性な低分子量変異体
CN111050784B (zh) 2017-08-11 2024-03-19 伊利诺伊大学理事会 截短的豚鼠l-天冬酰胺酶变体及其使用方法
JP7545894B2 (ja) 2018-03-13 2024-09-05 アフィボディ アクティエボラーグ 新規足場に基づくポリペプチド
KR102282240B1 (ko) * 2018-12-06 2021-07-28 경상국립대학교산학협력단 지속형 엑센딘-4 및 이의 용도
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
EP4045061A4 (en) 2019-10-14 2024-04-17 ARO Biotherapeutics Company FIBRONECTIN TYPE III DOMAINS BINDING TO CD137
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
WO2021127353A1 (en) * 2019-12-18 2021-06-24 Aro Biotherapeutics Company Serum albumin-binding fibronectin type iii domains and uses thereof
WO2021174107A2 (en) 2020-02-26 2021-09-02 Northwestern University Soluble ace2 variants and uses therefor
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
JP2024517610A (ja) 2021-04-14 2024-04-23 アロ・バイオセラピューティクス・カンパニー Cd71に結合するフィブロネクチンiii型ドメイン
CN113336860B (zh) * 2021-06-02 2022-07-01 北京大学 一种具有靶向和长效功能的重组水蛭素融合蛋白及其编码基因和应用
EP4615859A2 (en) * 2022-11-09 2025-09-17 Repligen Corporation Affinity agents
EP4634216A1 (en) 2022-12-16 2025-10-22 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025125378A1 (en) * 2023-12-12 2025-06-19 Navigo Proteins Gmbh Novel serum albumin-binding fusion proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011137319A2 (en) 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
WO1993022439A1 (en) * 1992-05-07 1993-11-11 Microbiological Research Authority Immunoglobulin binding proteins derived from l protein and their uses
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US6670127B2 (en) 1997-09-16 2003-12-30 Egea Biosciences, Inc. Method for assembly of a polynucleotide encoding a target polypeptide
DE69841578D1 (de) 1997-09-16 2010-05-06 Centocor Inc Methoden zur kompletten chemischen Synthese und Zusammensetzung von Genen und Genomen
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
WO2001045746A2 (en) 1999-12-24 2001-06-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
DE08786222T1 (de) 2007-07-31 2010-11-25 Affibody Ab Neue albuminbindende zusammensetzungen, verfahren und anwendungen
CA2729567C (en) 2008-06-30 2018-04-24 Kyowa Hakko Kirin Co., Ltd. Anti-cd27 antibody
CN102307896B (zh) * 2008-10-31 2016-10-12 森托科尔奥索生物科技公司 基于iii型纤连蛋白结构域的支架组合物、方法及用途
EP2397547A4 (en) * 2009-02-10 2012-09-05 Univ Ryukyus DRUG CARRIER AND ADJUVANT AND VACCINE USING EACH
CA2752211C (en) 2009-02-12 2020-03-24 Janssen Biotech, Inc. Fibronectin type iii domain based scaffold compositions, methods and uses
KR101958753B1 (ko) 2010-04-13 2019-03-15 셀덱스 쎄라퓨틱스, 인크. 인간 cd27에 결합하는 항체 및 이의 용도
US9695228B2 (en) * 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2011137319A2 (en) 2010-04-30 2011-11-03 Centocor Ortho Biotech Inc. Stabilized fibronectin domain compositions, methods and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Jacobs, S.A. ET AL., PROTEIN ENG DES SEL, vol. 25, pp. 107-117 (2012.01.12.)
JONSSON, A. ET AL., PROTEIN ENG DES SEL, vol. 21, pp. 515-527 (2008.01.01.)

Also Published As

Publication number Publication date
JP2021019595A (ja) 2021-02-18
EP2855509A4 (en) 2016-01-13
JP2015519345A (ja) 2015-07-09
AU2013266215A1 (en) 2014-12-04
EA036487B1 (ru) 2020-11-16
IL254652A0 (en) 2017-11-30
CA2874646C (en) 2020-12-01
US10280200B2 (en) 2019-05-07
MX2014014384A (es) 2015-05-11
BR112014029409B1 (pt) 2022-11-29
US20130316952A1 (en) 2013-11-28
BR112014029409A2 (enExample) 2017-08-15
IL235808A (en) 2017-10-31
DK2855509T3 (en) 2018-07-23
EP2855509B1 (en) 2018-05-02
CN104470944A (zh) 2015-03-25
KR20150016585A (ko) 2015-02-12
AU2013266215B2 (en) 2017-12-07
CA2874646A1 (en) 2013-11-28
EA201590136A1 (ru) 2016-02-29
CN104470944B (zh) 2021-09-14
JP7166081B2 (ja) 2022-11-07
WO2013177398A3 (en) 2014-03-27
PT2855509T (pt) 2018-08-03
US20180009854A1 (en) 2018-01-11
US9156887B2 (en) 2015-10-13
US20160083436A1 (en) 2016-03-24
AU2017261625A1 (en) 2017-12-07
ES2670442T3 (es) 2018-05-30
HK1209134A1 (en) 2016-03-24
EP2855509A2 (en) 2015-04-08
JP2018171063A (ja) 2018-11-08
WO2013177398A2 (en) 2013-11-28
MX355041B (es) 2018-03-28
IL254652B (en) 2019-12-31
IL235808A0 (en) 2015-01-29
AU2017261625B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
KR102053674B1 (ko) 비-천연 컨센서스 알부민 결합 도메인
CN102781960B (zh) Hsa相关组合物及使用方法
KR102461666B1 (ko) 혈청 알부민 결합 피브로넥틴 iii 형 도메인
CN105477641A (zh) 生物合成的脯氨酸/丙氨酸无规卷曲多肽及其用途
WO2012088006A1 (en) Fibronectin based scaffold domain proteins that bind il-23
CA2837875A1 (en) Human fusion proteins comprising interferons and targeted modified ubiquitin proteins
WO2013186329A1 (en) Human fusion proteins comprising single chain tnfalpha and targeting domains
US6492492B1 (en) Circularly permuted biotin binding proteins
HK1209134B (en) Non-natural consensus albumin binding domains
EA045108B1 (ru) Выделенный искусственный альбумин-связывающий домен и содержащий его слитый белок
JP6525171B2 (ja) 環状化サイトカイン及びその製法
CN117858982A (zh) 人纤连蛋白iii型蛋白支架

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7